Recombinant snake antivenoms get closer to the clinic

Andreas H. Laustsen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

4 Downloads (Pure)


Snakebite envenomings kill ~100 000 victims each year and leave many more with permanent sequelae. Antivenoms have been available for more than 125 years but are in need of innovation. A new study by Khalek et al. highlights broadly neutralizing human monoclonal antibodies (mAbs) that might be used to develop recombinant antivenoms with superior therapeutic benefits.
Original languageEnglish
JournalTrends in Immunology
Issue number4
Pages (from-to)225-227
Publication statusPublished - 2024


Dive into the research topics of 'Recombinant snake antivenoms get closer to the clinic'. Together they form a unique fingerprint.

Cite this